Neurological Disease: Early-Stage R&D and Dealmaking
Decision Resources
August 20, 2009 25 Pages - SKU: DECR2427941
|
|
Introduction
How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology
drug market? Although brimming with potential, neurology drug development is also rife with unique
challenges that many companies and agents have been unable to overcome, as witnessed by the failures
of agents initially deemed highly promising. However, careful planning-including risk mitigation
through strategic collaboration-can allow a drug developer to take advantage of the significant
opportunity in this market.
Questions Answered in This Report
- Although therapies are available for neurological disorders, most of these conditions remain undertreated,
and no cures are available. What benefits do novel therapies have over existing treatment
options? How can companies mitigate the risk associated with drug development?
- Much of the innovation in drug discovery and design occurs in small companies. What companies
are developing novel approaches to treat neurological diseases? What collaborations have they
forged with Big Pharma?
- The neurology market is entering a period of stagnation. What is currently driving market
growth? What are the greatest needs in the treatment of neurological diseases?
Scope
- Novel targets for neurology: Beta-amyloid, beta-secretase, tau protein, NMDA, nicotinic
acetylcholinesterase receptor, HMG-CoA reductase.
- Novel technologies for neurology: Deep-brain stimulation, stem cell therapy.
- Focus on diseases with neuronal degradation as a primary symptom: Alzheimer's disease
(AD), mild cognitive impairment (MCI), multiple sclerosis (MS), Parkinson's disease
(PD), Huntington's disease (HD), ALS and other motor neuron diseases.
- Company profiles: Lundbeck, CoMentis, Targacept, Vitae Pharmaceuticals.
- Outlook: Challenges in drug development, recent dealmaking, need for increased research,
benefits of academic collaborations.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Neurology Market: Poised for Change and Innovation
- Novel Approaches to Neurological Disease Treatment
- Novel Targets
- Beta-Amyloid
- Beta-Secretase
- Tau Protein
- NMDA
- Nicotinic Receptors
- HMG-CoA Reductase
- Novel Technologies
- Stem Cell Therapy
- Deep-Brain Stimulation
- Company Profiles
- Lundbeck
- CoMentis
- Targacept
- Vitae Pharmaceuticals
- Outlook
- Tables
- 1. Descriptions of Select Neurological Diseases
- 2. Top-Selling Products for the Treatment of Neurological Diseases, 2008
- 3. Beta-Amyloid Agents in Clinical Development for the Treatment of Neurological Diseases
- 4. Beta-Secretase Agents in Clinical Development for the Treatment of Neurological Diseases
- 5. Tau Protein Agents in Clinical Development for the Treatment of Neurological Diseases
- 6. NMDA Agents in Clinical Development for the Treatment of Neurological Diseases
- 7. Nicotinic Receptor Agents in Clinical Development for the Treatment of Neurological Diseases
- 8. Benefits and Drawbacks of Stem Cell Types in the Treatment of Neurological Diseases
- 9. Select Companies Developing Stem Cell Therapies
- 10. Select Deals Focusing on the Development of Neurological Disease Treatments
- Figures
- 1. Worldwide Neurology Market Growth, 2004-2008
- 2. Areas of the Brain Targeted by Deep Brain Stimulation
Share this report
Other tasks Related Markets CNS/Neurology Reports- Traumatic Brain Injury Global Clinical Trials Review, H1, 2012
- Tension -Type Headache Global Clinical Trials Review, H1, 2012
- Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012
- Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012
- Brain Ischemia Global Clinical Trials Review, H1, 2012
Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
